CDH backs Chinese healthcare AI business

HY was founded by Xiangfei Chai and Lei Xing, a Stanford University graduate and professor, respectively, and technology professional Na Guo in 2015. Through AI and big data analysis, HY aims to improve the efficiency and accuracy of medical image reading for cancer.

The company claims it takes only five seconds for its system to analyze an image and reach the same conclusions as a senior doctor. For breast tumor diagnosis, HY claims its technology has an accuracy rate of 91%. More than 700 Chinese hospitals use HY solutions, the company said.

HY raised a Series A round of funding from BlueRun Ventures in 2016, and a Series B round worth hundreds of millions renminbi last year, led by Delta Capital. The latest funding will go towards further commercialization of the company's technology. 

CDH said in a statement that it is looking at AI applications across various industries. The firm finds medical imaging particularly interest in this context because it can generate a lot of data with broader applications in the healthcare space.

CDH previously invested in SenseTime Technology, an AI and deep learning technology start-up. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Technology
• Healthcare
• Expansion
• China
• CDH Investments Management
• TMT
• Growth capital
• Venture